Antiglaucoma pharmacotherapy

C P Tătaru, V L Purcărea, C P Tătaru, V L Purcărea

Abstract

This review presents the pharmacotherapeutic approaches available in the treatment of glaucomatous optic neuropathy. Although its etiology is multi-factorial, currently, the main therapy is to decrease intraocular pressure. New therapies are being developed; the current trend is a retinal ganglion cell neuroprotection. Neuroprotection is achieved by combining antihypertensive agents with drugs that directly protect the optic nerve by promoting cell survival and inhibition of neuronal signals that initiate apoptosis. The treatment should also preserve the ocular hemodynamics, ensure proper patient compliance and be free of side effects.

Keywords: Fixed combinations; Glaucoma; Monotherapy; Neuroprotection.

References

    1. Brubaker RF. Mechanism of action of bimatoprost (Lumigan) . Surv Ophthalmol. 2001;45:S347–S351.
    1. Calugaru M. The effect of levobunolol eyedrops on trabecular outflow of aqueous humor in chronic simple glaucoma. Klin Monatsbl Augenheilkd. 1989;194:164–169.
    1. Cantor LB. An update on bimatoprost in glaucoma therapy. Expert Opin Pharmacother. 2002;3:1753–1762.
    1. European Glaucoma Society Terminology and guidelines for glaucoma. 2008
    1. Goldberg I. Betaxolol. Aust N Z J Ophthalmol. 1989;17:9–13.
    1. Hoyng PF. Pharmacological therapy for glaucoma: A review. Drugs. 2000;59:411–434.
    1. Izzotti A. The role of oxidative stress in glaucoma. Mutat Res. 2006;612:105–114.
    1. Kumarasamy NA. Glaucoma: Current and developing concepts for inflammation, pathogenesis and treatment. Eur J Inflamm. 2006;4:129–137.
    1. Lesar TS, compiler. In: Pharmacotherapy: A pathophysiologic approach, 4th ed. Stamford, Connecticut: Appleton and Lange; 1999. pp. 1466–1478.
    1. Marquis RE. Management of glaucoma: Focus on pharmacological therapy. Drugs Aging. 2005;22:1–21.
    1. Novack GD. New glaucoma medications in the geriatric population: Efficacy and safety. J Am Geriatr Soc. 2002;50:956–962.
    1. Robert EM. Management of glaucoma: Focus on pharmacological therapy. Drugs Aging. 2005;22:1–21.
    1. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt): A new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400–408.
    1. Soltau J. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol. 2002;47:S2–S5.
    1. Stewart WC. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol. 1997;124:498–505.
    1. Tataru C. Aspecte clinice în glaucoma. Viata Medicala. 2004;28:1–3.
    1. Tataru C. Tratamentul glaucomului. Viata Medicala. 2004;31:2–4.
    1. Trawick AB. Potential systemic and ocular side effects associated with topical administration of timolol maleate. J Am Optom Assoc. 1985;56:108–112.
    1. Zimmerman TJ, compiler. In: Textbook of Ocular Pharmacology, Philadelphia: Lippincott-Raven; 1997.
    1. Zimmerman TJ. Topical ophthalmic beta blockers: A comparative review. . J Ocul Pharmacol. 1993;9:373–384.
    1. [Internet] WHO report; 2002. Available from: .
    1. Wistrand PJ. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41:S129–S138.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir